知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.029 seconds)

    Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use
    1.
    发明申请
    Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use 有权
    包含用于治疗疼痛或炎症的生物膜密封剂的组合物和使用方法

    公开(公告)号：US20070258938A1

    公开(公告)日：2007-11-08

    申请号：US11418153

    申请日：2006-05-03

    Applicant: Josee Roy ,  William McKay ,  Jeffrey Marx

    Inventor： Josee Roy ,  William McKay ,  Jeffrey Marx

    IPC: A61K31/787 ,  A61K31/717 ,  A61K31/765

    CPC classification number: A61K33/14 ,  A61K9/0019 ,  A61K9/0085 ,  A61K31/717 ,  A61K31/765 ,  A61K31/787 ,  A61K33/06 ,  A61K2300/00

    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

    Abstract translation: 本发明提供了治疗疼痛或炎症的方法和试剂盒。 在一个实施方案中，试剂盒包括生物膜密封剂，例如PEG，以及生物活性剂，例如镁化合物。 生物膜密封剂和/或生物活性剂，静脉内给药，肌内给药，鞘内给药，皮下给药，硬膜外给药，胃肠外给药，关节内给药，直接施用于或邻近 病理状况及其任何组合。 或者，生物膜密封剂和/或生物活性剂可以从泵或植入物递送。

    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
    2.
    发明申请
    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use 有权
    包含用于治疗神经元损伤的生物膜密封剂的组合物和使用方法

    公开(公告)号：US20070259044A1

    公开(公告)日：2007-11-08

    申请号：US11418152

    申请日：2006-05-03

    Applicant: Josee Roy ,  William McKay ,  Jeffrey Marx

    Inventor： Josee Roy ,  William McKay ,  Jeffrey Marx

    IPC: A61K38/20 ,  A61K38/18 ,  A61K38/11 ,  A61K38/05 ,  A61K31/65 ,  A61K31/56 ,  A61K9/14

    CPC classification number: A61K33/06 ,  A61K9/0019 ,  A61K31/56 ,  A61K31/65 ,  A61K31/765 ,  A61K47/10

    Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

    Abstract translation: 本发明提供用于治疗神经元损伤的组合物，试剂盒和方法。 在一个实施方案中，组合物包含生物膜密封剂，例如PEG，以及生物活性剂，例如镁化合物。 静脉内给药，肌内给药，鞘内给药，皮下给药，硬膜外给药，胃肠外给药，直接施用于病理状况的部位或其附近的生物膜密封剂和/或生物活性剂，以及任何 其组合。 或者，生物膜密封剂和/或生物活性剂可以从泵或植入物递送。

    Pharmaceutical removal of vascular and/or neuronal extensions form a degenerating disc
    3.
    发明申请
    Pharmaceutical removal of vascular and/or neuronal extensions form a degenerating disc 有权
    血管和/或神经元延伸的药物去除形成退化的椎间盘

    公开(公告)号：US20070253930A1

    公开(公告)日：2007-11-01

    申请号：US11414689

    申请日：2006-04-28

    Applicant: Josee Roy ,  Susan Drapeau ,  Jeffrey Marx

    Inventor： Josee Roy ,  Susan Drapeau ,  Jeffrey Marx

    IPC: A61K38/21 ,  A61K38/18

    CPC classification number: A61K38/1825 ,  A61K38/185 ,  A61K38/1858 ,  A61K38/2093 ,  A61K38/212

    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

    Abstract translation: 本发明提供了一种通过施用破坏椎间盘中的神经元和/或血管元件（通常是退化的椎间盘）的治疗剂来减轻椎间盘突出症的方法。 磁盘中的神经元元件的破坏包括破坏神经末梢，而不会显着影响神经的中枢体，抑制神经末梢的激活，并抑制神经末梢进入椎间盘的生长。 血管元件的破坏包括使血管延伸部从圆盘缩回，或抑制这种延伸部的形成。 治疗剂可以通过体内泵，推注或贮库局部给药，或者可以全身给药。

    Pharmaceutical removal of vascular extensions from a degenerating disc
    4.
    发明申请
    Pharmaceutical removal of vascular extensions from a degenerating disc 审中-公开
    药物从退化椎间盘移除血管延伸

    公开(公告)号：US20070253960A1

    公开(公告)日：2007-11-01

    申请号：US11413346

    申请日：2006-04-28

    Applicant: Josee Roy ,  Susan Drapeau ,  Jeffrey Marx

    Inventor： Josee Roy ,  Susan Drapeau ,  Jeffrey Marx

    IPC: A61K39/395

    CPC classification number: A61K31/16 ,  A61K31/337 ,  A61K31/573 ,  A61K38/179 ,  A61K38/18 ,  A61K2039/505

    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disc includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disc. Disruption of vascular elements includes causing the vascular extensions to retract from the disc, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

    Abstract translation: 本发明提供了一种通过施用破坏椎间盘中的神经元和/或血管元件（通常是退化的椎间盘）的治疗剂来减轻椎间盘突出症的方法。 盘中的神经元元件的破坏包括破坏神经末梢而基本上不影响神经的中枢体，抑制神经末梢的激活，并抑制神经末梢进入椎间盘的生长。 血管元件的破坏包括使血管延伸部从椎间盘缩回，或抑制这种延伸的形成。 治疗剂可以通过体内泵，推注或贮库局部给药，或者可以全身给药。

    Compositions and methods for treating pain
    6.
    发明申请
    Compositions and methods for treating pain 有权
    用于治疗疼痛的组合物和方法

    公开(公告)号：US20060280718A1

    公开(公告)日：2006-12-14

    申请号：US11444077

    申请日：2006-05-31

    Applicant: Josee Roy ,  Jeffrey Marx

    Inventor： Josee Roy ,  Jeffrey Marx

    IPC: A61K31/765 ,  A61K31/718 ,  A61K31/717 ,  A61K31/77

    CPC classification number: A61K31/765 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/00 ,  A61K45/06 ,  A61K47/10 ,  A61L31/06 ,  A61L31/16 ,  A61L2300/402 ,  A61L2400/06 ,  C08L71/02

    Abstract: In the present invention, Applicants demonstrate the effect of a biomembrane sealing agent on the development of chronic pain following tissue injury as well as acute pain in a model of acute inflammation. Applicants demonstrate the ability of this class of agents referred to as “biomembrane sealing agents” to reduce the severity of hyperalgesia and allodynia following mechanical insult to the nervous system as well as their ability to reduce acute pain in a model of acute inflammation. Applicant describes the use of injectable or depot formulations of biomembrane sealing agent(s) for prophylactic treatment such as they could be administered after the insult (i.e. post-injury or post-surgery) but before the onset of acute or chronic pain. Alternatively, biomembrane sealing agents could be used to reduce the severity of acute or chronic pain after onset.

    Abstract translation: 在本发明中，申请人证明了生物膜密封剂对组织损伤后慢性疼痛的发展以及急性炎症模型中的急性疼痛的影响。 申请人证明了这种被称为“生物膜密封剂”的药剂在机械损伤神经系统以及在急性炎症模型中减少急性疼痛的能力的降低痛觉痛和异常性疼痛的严重性的能力。 申请人描述了用于预防性治疗的生物膜密封剂的可注射或储存制剂的使用，例如它们可以在侮辱（即损伤后或术后）之后但在急性或慢性疼痛发作之前施用。 或者，可以使用生物膜密封剂来降低发作后的急性或慢性疼痛的严重性。

    Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1)
    7.
    发明申请
    Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1) 有权
    LIM矿化蛋白-1（LMP-1）诱导骨诱导机制

    公开(公告)号：US20070027081A1

    公开(公告)日：2007-02-01

    申请号：US11385612

    申请日：2006-03-21

    Applicant: Jeffrey Marx ,  William McKay ,  Scott Boden

    Inventor： Jeffrey Marx ,  William McKay ,  Scott Boden

    IPC: A61K38/17 ,  A61K38/00

    CPC classification number: A61K38/1709 ,  A61K38/1875 ,  A61K2300/00

    Abstract: The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.

    Abstract translation: 本发明涉及用于治疗受损骨患者的方法和组合物。 具体地，本发明涉及包括LIM矿化蛋白（特别是LMP-1）的小分子和肽模拟物的组合治疗策略，以克服BMP-2治疗剂的剂量相关翻译屏障。

    Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation
    9.
    发明申请
    Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation 审中-公开
    分离富含结缔组织生长成分的骨髓部分及其促进结缔组织形成的用途

    公开(公告)号：US20050130301A1

    公开(公告)日：2005-06-16

    申请号：US10887275

    申请日：2004-07-08

    Applicant: William McKay ,  Jeffrey Marx

    Inventor： William McKay ,  Jeffrey Marx

    IPC: A61K35/28 ,  A61K38/18 ,  A61L27/36 ,  A61L27/38 ,  A61L27/48 ,  A61L27/56 ,  C12N5/08

    CPC classification number: A61L27/3691 ,  A61K35/28 ,  A61K38/1875 ,  A61L27/3608 ,  A61L27/3616 ,  A61L27/38 ,  A61L27/48 ,  A61L27/56 ,  A61K2300/00

    Abstract: A bone marrow isolate rich in one or more connective tissue growth components, methods of forming the isolate, and methods of promoting connective tissue growth using the isolate are described. A biological sample comprising bone marrow is centrifuged to separate the sample into fractions including a fraction rich in connective tissue growth components. The fraction rich in connective tissue growth components is then isolated from the separated sample. The isolate can be used directly or combined with a carrier and implanted into a patient at a tissue (e.g., bone) defect site. The biological sample can comprise bone marrow and whole blood. The isolate can be modified (e.g., by transfection with a nucleic acid encoding an osteoinductive polypeptide operably linked to a promoter) prior to application to the tissue defect site. The isolate can be made and applied to the tissue defect site in a single procedure (i.e., intraoperatively).

    Abstract translation: 描述了富含一种或多种结缔组织生长组分的骨髓分离物，形成分离物的方法和使用该分离物促进结缔组织生长的方法。 将包含骨髓的生物样品离心以将样品分离成包含富含结缔组织生长成分的馏分。 然后从分离的样品中分离富含结缔组织生长成分的级分。 分离物可以直接使用或与载体组合使用，并在组织（例如骨）缺陷部位植入患者体内。 生物样品可以包括骨髓和全血。 在施用于组织缺损位点之前，可以修饰分离物（例如，通过用编码与促进剂可操作地连接的骨诱导多肽的核酸进行转染）。 分离物可以以单一程序（即在手术中）制成并应用于组织缺损部位。

Patent Agency Ranking